Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Stopped The trial was terminated prematurely due to difficulties with recruitment because of the COVID-19 pandemic.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
- DRUG: Nintedanib
- OTHER: Pulmonary rehabilitation program
Sponsor
Boehringer Ingelheim